ArticleSkin health and disease2026
Unmasking: paronychia as the hidden face of pemphigus.
Article in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pemphigus vulgaris (PV) is a rare, potentially life-threatening autoimmune blistering disorder primarily affecting the skin and mucous membranes. We present a unique case of delayed diagnosis in a patient with PV, initially manifesting as isolated, extensive and therapy-resistant paronychia. PV was only considered after the appearance of mucocutaneous lesions - first oral, then cutaneous - more than 1 year after symptom onset. Diagnosis was ultimately established through histopathological examination, direct immunofluorescence and serological testing. Following diagnosis, the patient received rituximab therapy, resulting in a rapid and sustained clinical remission. This case underscores the importance of considering PV in the differential diagnosis of severe, chronic and treatment-resistant paronychia. Early recognition and diagnosis are crucial for timely intervention, which can significantly improve patient outcomes. Rituximab proved highly effective in this case, aligning with current evidence supporting its use as a first-line treatment for PV. We aim to raise awareness of atypical PV presentations and stress the need for thorough evaluation of persistent, treatment-resistant paronychia to prevent delayed diagnosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.